Specific TNFI and risk of non-viral opportunistic infections in RA patients
| Exposures | Events | Person-years | Crude rate (per 1000 person-years), 95% CI | Adjusted HR* |
|---|---|---|---|---|
| Comparison of specific TNFI to non-biological DMARD | ||||
| Non-biological DMARD | 13 | 7443 | 1.7 (1.0 to 3.0) | 1.00 (Reference) |
| Etanercept | 13 | 8641 | 1.5 (0.9 to 2.6) | 0.8 (0.4, 1.8) |
| Any baseline glucocorticoid use | 1.7 (0.7, 4.1) | |||
| Non-biological DMARD | 13 | 7443 | 1.7 (1.0 to 3.0) | 1.00 (Reference) |
| Adalimumab | 15 | 4282 | 3.5 (2.1 to 5.8) | 1.8 (0.6, 5.3) |
| Any baseline glucocorticoid use | 2.8 (0.8, 9.9) | |||
| Non-biological DMARD | 13 | 7443 | 1.7 (1.0 to 3.0) | 1.00 (Reference) |
| Infliximab | 55 | 13 519 | 4.1 (3.1 to 5.3) | 2.6 (1.2, 5.6) |
| Any baseline glucocorticoid use | 1.7 (0.9, 3.4) | |||
| Comparison of specific TNFI to etanercept | ||||
| Etanercept | 13 | 8641 | 1.5 (0.9 to 2.6) | Reference |
| Adalimumab | 15 | 4282 | 3.5 (2.1 to 5.8) | 1.8 (0.8, 4.0) |
| Any baseline glucocorticoid use | 2.5 (0.9, 7.3) | |||
| Etanercept | 13 | 8641 | 1.5 (0.9 to 2.6) | Reference |
| Infliximab | 40 | 9263 | 4.3 (3.2 to 5.9) | 2.9 (1.5, 5.4) |
| Any baseline glucocorticoid use | 1.6 (0.8, 3.1) | |||
*Adjusted by propensity score quintile and baseline glucocorticoid use 1 year before time zero (reference=no use).
Estimates were stratified by site and all 95% CI were based on robust SE.
DMARD, disease-modifying anti rheumatic drug; RA, rheumatoid arthritis; TNFI, tumour necrosis factor α inhibitor.